Table 1.
Cancer Model | Tumor type | Treatment | Route | Ref. |
---|---|---|---|---|
Xenograft | Pancreas | 250 mg/kg | IP | [127] |
Lung | 50 mg/kg | Oral | [158] | |
Colon | 250 mg/kg | IP | [142] | |
Prostate | 200 μg/ml 1 mg/day |
Oral IP |
[134] | |
Breast | 2 mg/ml | Oral | [138] | |
Leukemia | 250 mg/kg | IP | [124] | |
Cancer stem cells | 100 μg/ml | IP | [159] | |
chemically-induced | Breast | 50–500 mg/kg | Oral | [160] |
Lung | 250 mg/kg | IP | [161] | |
Colon | 250 mg/kg | IP | [162] | |
Pancreas | 320 mg/kg | Oral | [115] | |
HER2/neu mice | Breast | 100 mg/kg | Oral | [118] |
PTEN+/− mice | All | 300 mg/kg | Oral | [119] |
APCMin/+ mice | Gastrointestinal polyps | 250 mg/kg | Oral | [120] |